← Leaderboards
Kyuyeon Han
University Of Illinois At Chicago
$1,638,975
Attributed
$1,638,975
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $639.6K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,638,975 · 2
By mechanism
R01$1,199,250 · 1
R21$439,725 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Sriram Ravindran$3,008,157
- Praveen Gajendrareddy$1,976,855
- Deepak Shukla$19,733,938
- Anne George$13,620,882
- Andrew D Mesecar$12,210,126
Others in their field
Other Rising Stars on “Specificity”
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Brian Zavertnik · Palantir Technologies, Inc.$22,886,494
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Bambra Stokes · Ppd Development Lp$17,155,112
Research focus
SpecificityCellsMediatingReportingNovel TherapeuticsMmp14 GeneInnovationMatrix MetalloproteinasesMolecular Biology TechniquesProteinsTherapeutic AgentsBindingBiophysicsMutantExperimental StudyExtracellular MatrixCorneaIn VitroAnimal ModelEffectivenessAngiostatinsClioquinolAnalogEndostatins
Grant awards (5)
Identification of a new role of membraneâtype 1 matrix metalloproteinases in corneal neovascularization$399,750
R01 · FY2025 · EY · contact PI
Identification of a new role of membraneâtype 1 matrix metalloproteinases in corneal neovascularization$399,750
R01 · FY2024 · EY · contact PI
Development of MMP14-laden exosomes as a novel anti-SARS-CoV-2 therapy$239,850
R21 · FY2024 · AI · contact PI
Identification of a new role of membraneâtype 1 matrix metalloproteinases in corneal neovascularization$399,750
R01 · FY2023 · EY · contact PI
Development of MMP14-laden exosomes as a novel anti-SARS-CoV-2 therapy$199,875
R21 · FY2023 · AI · contact PI